All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

CEACAM5 Shows Great Potential as Therapeutic Target in NSCLC

September 7th 2022

Paul Bunn, MD, elaborates on carcinoembryonic antigen–related cell adhesion molecule 5 as a potential target in the treatment of non–small cell lung cancer.

Pre- and Co-administration of Nivolumab Proves Safe in Locally Advanced Cervical Cancer Treated With CCRT

September 7th 2022

The addition of the pre- and co-administration of nivolumab with concurrent chemoradiation appeared to be safe and feasible in patients with locally advanced cervical carcinoma, according to data from the phase 1 GOTIC-018 trial.

Second-line Ramucirumab Showcases Survival Benefits in HCC, Irrespective of Extrahepatic Spread

September 7th 2022

Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.

Black Patients With HCC, Those Living in High-Poverty Neighborhoods Have Higher Odds of Experiencing Treatment Delays

September 6th 2022

Data from a recent analysis revealed that nearly 1 in 7 patients with hepatocellular carcinoma experience treatment delays, with higher odds observed in Black patients and those living in high poverty neighborhoods.

FDA Approves Pegfilgrastim Biosimilar for Febrile Neutropenia

September 6th 2022

The FDA has approved the biosimilar pegfilgrastim for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Surgical Complications Unrelated to Timing of Neoadjuvant Chemotherapy in Lower-Extremity Sarcomas

September 6th 2022

R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.

Sequential Combo of Regorafenib and Nivolumab Shows Manageable Safety in Sorafenib-Pretreated HCC

September 6th 2022

The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.

Florida Cancer Specialists & Research Institute Furthers Commitment to Clinical Research and Innovation, Next-Generation Sequencing in Advancement of Cancer Care

September 6th 2022

Florida Cancer Specialists & Research Institute announced the formation of additional precision oncology capabilities and resources comprised of geneticists, informatics specialists, and database technologies that will enhance patient care through comprehensive analysis of molecular data.

Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma

September 6th 2022

Immunotherapy in the form of ipilimumab plus nivolumab followed by the targeted therapy combination encorafenib plus binimetinib elicited an overall survival benefit in patients with untreated BRAF-mutated metastatic melanoma, according to findings from the phase 2 SECOMBIT trial.

New JAK Inhibitors and Emerging Novel Agents Expand Myelofibrosis Treatment Arsenal

September 6th 2022

A panel of hematology cancer experts discuss the current treatment landscape and novel emerging therapies for patients with myelofibrosis.

Real-World Data Highlight Efficacy of Ide-cel in Patients With Relapsed/Refractory Multiple Myeloma

September 6th 2022

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Patients With Bone Sarcomas of Lower-Extremity and Non-Private Insurance Linked With Higher Amputation Rates, Worse Outcomes

September 5th 2022

Amputation is an independent predictor of poor outcomes among patients with high-grade bone sarcoma of lower extremity, and non-private insurance was found to be linked with increased likelihood of amputation and an advanced stage at presentation in this patient population.

Investigators Set Sights on Optimizing CAR T-Cell Therapy in Lymphoma

September 4th 2022

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

Neoadjuvant Therapy Holds Promise for Patients With Locally Advanced Rectal Cancer

September 4th 2022

Research published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.

Investigative Approaches Seek to Enhance Outcomes for Patients With CDK12-Mutant mCRPC

September 3rd 2022

DNA damage homologous recombination repair genotypic variants are not created equal.

Daratumumab Compliance Rates in Multiple Myeloma Maintained in Real-World Analysis

September 2nd 2022

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

Fixed-Duration Bendamustine/Rituximab Is Beneficial Irrespective of Mutation Status in Waldenström Macroglobulinemia

September 2nd 2022

Fixed-duration bendamustine plus rituximab was effective in patients with previously untreated Waldenström macroglobulinemia, regardless of MYD88L265P mutation status, but the presence of the CXCR4WHIM mutation may be associated with resistance to the combination.

FDA Approves Durvalumab Plus Gemcitabine/Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancers

September 2nd 2022

The FDA has approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin in adult patients with locally advanced or metastatic biliary tract cancers.

Sacituzumab Govitecan Provides PFS Benefit Vs Chemotherapy in HR+/HER2– Breast Cancer

September 2nd 2022

Sacituzumab govitecan displayed encouraging progression-free survival rates compared with single-agent chemotherapy in patients with locally recurrent inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer, according to findings from the phase 3 TROPiCS-02 study.

Social Determinants and Genetics Work in Tandem to Drive Disparities in Breast Cancer Care

September 2nd 2022

Adana A.M. Llanos, PhD, MPH, discusses key research on the social and biological factors that influence disparities in breast cancer, how these factors work in tandem to affect patient outcomes, and how this knowledge can be deployed in the real world.